权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Structure-Guided Design of Intestine-Selective AHR Agonists for Restoration of Gut Barrier Integrity in IBD

用于恢复 IBD 肠道屏障完整性的肠道选择性 AHR 激动剂的结构引导设计

基本信息

批准号：
10627922
负责人：
Elliot Chaikof
金额：
$ 70.59万
依托单位：
BETH ISRAEL DEACONESS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-06-01 至 2026-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10627922
关键词：
Acceleration Adaptor Signaling Protein Adult Agonist Antibodies Aryl Hydrocarbon Receptor Bacterial Translocation Biodistribution Cells Chemicals Coculture Techniques Colitis Dose Drug Design Effectiveness Ensure Epithelium Exhibits Functional disorder Generations Genetic Polymorphism Gut Mucosa Homeostasis Human Immune Immune system Immunity Immunologic Receptors Immunomodulators Indoles Infection Inflammatory Bowel Diseases Inflammatory Response Innate Immune System Intervention Intestines Invaded Investigation Lead Ligands Maintenance Malignant Neoplasms Mediating Modeling Mucosal Immune Responses Mucosal Immune System Mucous Membrane Mus Oral Administration Organoids Parents Pathogenicity Pathway interactions Patients Pharmaceutical Preparations Phase Predisposition Prevention Process Production Protocols documentation Reporting Risk Safety Science Signal Transduction Structure Susceptibility Gene T-Lymphocyte Therapeutic Tissues Toxic effect Treatment Efficacy aryl hydrocarbon receptor ligand computer studies cost design dietary disorder risk drug candidate dysbiosis enteritis epithelial repair experimental study gastrointestinal epithelium genome wide association study genotoxicity healing in vivo infection risk interleukin-22 intestinal epithelium lead optimization microbial microorganism mouse model murine colitis pharmacokinetics and pharmacodynamics plant metabolites pyridine rational design repaired restoration scaffold

项目摘要

Project Summary At least one-third of patients with inflammatory bowel disease (IBD) do not respond appropriately to existing therapies and conventional agents remain limited by an increased risk of infection or malignancy, anti- drug antibodies, and high cost. Recent evidence now suggests that the exacerbated inflammatory response observed in IBD is initiated and maintained by loss of gut epithelial integrity with an ensuing dysbiosis and accompanying bacterial translocation and invasion. Crucial to the maintenance of epithelial barrier integrity, as well as gut microbial homeostasis and protection from pathogenic microorganisms is the mucosal immune system. The aryl hydrocarbon receptor (AHR) is an essential regulator of the gut immune system and mediates processes, including the expression of IL-22, which are responsible for gut tissue integrity, epithelial repair, and microbial homeostasis. We have recently discovered a new class of highly potent and drug-like AHR agonists derived from an indole-pyridine scaffold, which are suitable for oral administration and display promising pharmacokinetic (PK) and pharmacodynamics profiles. In this proposal we intend to: (1) Determine the modes of action of first-generation AHR agonists based on an indole-pyridine scaffold in complementary models of gut barrier dysfunction. In the first phase of our investigations, we will define the extent to which first-generation drug candidates mediate intestinal repair by modulating either the mucosal immune response or through a direct effect on the epithelium in complementary mouse models of enteritis. In the second phase, the ability of lead drug candidates to enhance intestinal integrity will be further evaluated using primary gut organoids, as well as through the use of gut organoid/immune cell co-culture models. (2) Design of intestine-selective AHR agonists with limited systemic exposure. We believe that design strategies that limit systemic activation of AHR will further enhance the safety profile of this important class of compounds. Our established lead compounds will be used as parent structures to explore the incorporation of substituents, as well as the design of antedrugs, which reduce systemic exposure. The druggable chemical space will be defined to ensure successful identification of gut-selective AHR agonists that display preferential activation of AHR in intestinal tissue with limited systemic exposure. We will confirm IL-22 induction in human T cells from healthy adults and adults with active IBD. (3) Characterize the effectiveness of intestine-selective AHR agonists in murine models of gut barrier dysfunction. Defining the therapeutic efficacy of intestine-selective AHR agonists for the prevention and treatment of IBD will be focus of the initial phase of these studies. Compound efficacy will be assessed in additional complementary murine models of enteritis in both prevention and intervention protocols. We will subsequently determine the safety profile, including genotoxicity, off-target selectivity, and dose-dependent toxicity for lead gut-selective compounds, which demonstrate significant in vivo potency and efficacy.

项目总结